יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Citius Oncology, Inc. (CTOR)

Citius Oncology, Inc. (CTOR) is developing anti-tumor methods through alliances with biotech giants to bring drugs to market. The business relies on collaboration with medical centers to implement targeted therapy for lymphomas. The company is currently preparing to launch a specialized treatment for T-cell skin lesions. The EV/EBITDA metric stands at 0.00, which is clearly demonstrated by the price chart on the GURU.Markets platform.

This indicator compares the total enterprise value, including debt, with its earnings before interest, taxes, depreciation, and amortization. The metric allows for an objective valuation of capital-intensive assets by excluding the influence of financing structures. The EV/EBITDA ratio dynamics for the company, accounting for debt load, reflect market expectations regarding resource management efficiency. For Citius Oncology, Inc. (CTOR), this is critically important when scaling sales of the drug LYMPHIR and expanding insurance coverage.